ketoconazole has been researched along with Polycystic Ovary Syndrome in 9 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
Polycystic Ovary Syndrome: A complex disorder characterized by infertility, HIRSUTISM; OBESITY; and various menstrual disturbances such as OLIGOMENORRHEA; AMENORRHEA; ANOVULATION. Polycystic ovary syndrome is usually associated with bilateral enlarged ovaries studded with atretic follicles, not with cysts. The term, polycystic ovary, is misleading.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the clinical efficacy of ketoconazole (KCZ) as an inhibitory enzyme on ovarian steroidogenesis, in prevention of ovarian hyper- stimulation syndrome (OHSS) during assisted reproductive technology (ART) in patients with polycystic ovarian syndrome (PCOS)." | 9.11 | The role of ketoconazole in the prevention of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during assisted reproductive technology cycles. ( Ahmadi, J; Amirchaghmaghi, E; Baghestani, AR; Owj, M; Tehrani-Nejad, ES, 2005) |
| "To evaluate the role of ketoconazole in prevention of ovarian hyperstimulation syndrome (OHSS) in women with the polycystic ovary syndrome (PCOS) undergoing ovarian stimulation with gonadotropins." | 9.10 | A double-blind, randomized, placebo-controlled study to assess the efficacy of ketoconazole for reducing the risk of ovarian hyperstimulation syndrome. ( Alborzi, S; Pakniat, M; Parsanezhad, ME; Schmidt, EH, 2003) |
| "To investigate the clinical efficacy of mild inhibition of ovarian steroidogenesis by very low-dose ketoconazole during induction of ovulation in patients with polycystic ovary syndrome (PCOS)." | 9.09 | Attenuation of ovarian response by low-dose ketoconazole during superovulation in patients with polycystic ovary syndrome. ( Barr, I; Diamant, YZ; Eldar-Geva, T; Gal, M; Margalioth, EJ; Orly, J, 1999) |
| "To investigate the effects of a low-dose ketoconazole on ovarian steroidogenesis and on serum androgen levels in polycystic ovary syndrome (PCOS)." | 7.69 | Low dose ketoconazole attenuates serum androgen levels in patients with polycystic ovary syndrome and inhibits ovarian steroidogenesis in vitro. ( Algur, N; Barr, I; Boldes, R; Diamant, YZ; Gal, M; Orly, J, 1994) |
| "Ketoconazole was given orally (400 mg/day) for 9 months to evaluate the effect of reduction in ovarian and adrenal androgens on insulin response (oral glucose tolerance test) in 35 women with polycystic ovary syndrome." | 5.29 | Reduction of endogenous, ovarian and adrenal androgens with ketoconazole does not alter insulin response in the polycystic ovary syndrome. ( Escobar-Jiménez, F; Garcia-Calvente, C; Jodar-Gimeno, E; Lardelli, P; Muñoz-Torres, M; Ruiz-Requena, ME; Vidal-Puig, A, 1994) |
| "To assess the clinical efficacy of ketoconazole (KCZ) as an inhibitory enzyme on ovarian steroidogenesis, in prevention of ovarian hyper- stimulation syndrome (OHSS) during assisted reproductive technology (ART) in patients with polycystic ovarian syndrome (PCOS)." | 5.11 | The role of ketoconazole in the prevention of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during assisted reproductive technology cycles. ( Ahmadi, J; Amirchaghmaghi, E; Baghestani, AR; Owj, M; Tehrani-Nejad, ES, 2005) |
| "To evaluate the role of ketoconazole in prevention of ovarian hyperstimulation syndrome (OHSS) in women with the polycystic ovary syndrome (PCOS) undergoing ovarian stimulation with gonadotropins." | 5.10 | A double-blind, randomized, placebo-controlled study to assess the efficacy of ketoconazole for reducing the risk of ovarian hyperstimulation syndrome. ( Alborzi, S; Pakniat, M; Parsanezhad, ME; Schmidt, EH, 2003) |
| "To investigate the clinical efficacy of mild inhibition of ovarian steroidogenesis by very low-dose ketoconazole during induction of ovulation in patients with polycystic ovary syndrome (PCOS)." | 5.09 | Attenuation of ovarian response by low-dose ketoconazole during superovulation in patients with polycystic ovary syndrome. ( Barr, I; Diamant, YZ; Eldar-Geva, T; Gal, M; Margalioth, EJ; Orly, J, 1999) |
| "To investigate the effects of a low-dose ketoconazole on ovarian steroidogenesis and on serum androgen levels in polycystic ovary syndrome (PCOS)." | 3.69 | Low dose ketoconazole attenuates serum androgen levels in patients with polycystic ovary syndrome and inhibits ovarian steroidogenesis in vitro. ( Algur, N; Barr, I; Boldes, R; Diamant, YZ; Gal, M; Orly, J, 1994) |
| "Polycystic ovary syndrome is the most common endocrinological problem associated with hirsutism." | 2.68 | Comparison of four different treatment regimes in hirsutism related to polycystic ovary syndrome. ( Gökmen, O; Gülekli, B; Işik, AZ; Senöz, S, 1996) |
| "BLA = bilateral adrenalectomy CD = Cushing disease CS = Cushing syndrome eCRF = electronic case report form MRI = magnetic resonance imaging PCOS = polycystic ovary syndrome." | 1.46 | BIOCHEMICAL CONTROL DURING LONG-TERM FOLLOW-UP OF 230 ADULT PATIENTS WITH CUSHING DISEASE: A MULTICENTER RETROSPECTIVE STUDY. ( Ayala, A; Biller, BMK; Bonert, V; Broder, MS; Carmichael, JD; Cherepanov, D; Eagan, M; Geer, EB; Gordon, MB; Hannoush, Z; Katznelson, L; Lalazar, Y; Lee, J; Manuylova, E; Neary, MP; Pulaski-Liebert, KJ; Said, Q; Shafiq, I; Surampudi, V; Swerdloff, RS, 2017) |
| "Ketoconazole was given orally (400 mg/day) for 9 months to evaluate the effect of reduction in ovarian and adrenal androgens on insulin response (oral glucose tolerance test) in 35 women with polycystic ovary syndrome." | 1.29 | Reduction of endogenous, ovarian and adrenal androgens with ketoconazole does not alter insulin response in the polycystic ovary syndrome. ( Escobar-Jiménez, F; Garcia-Calvente, C; Jodar-Gimeno, E; Lardelli, P; Muñoz-Torres, M; Ruiz-Requena, ME; Vidal-Puig, A, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (55.56) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Geer, EB | 1 |
| Shafiq, I | 1 |
| Gordon, MB | 1 |
| Bonert, V | 1 |
| Ayala, A | 1 |
| Swerdloff, RS | 1 |
| Katznelson, L | 1 |
| Lalazar, Y | 1 |
| Manuylova, E | 1 |
| Pulaski-Liebert, KJ | 1 |
| Carmichael, JD | 1 |
| Hannoush, Z | 1 |
| Surampudi, V | 1 |
| Broder, MS | 1 |
| Cherepanov, D | 1 |
| Eagan, M | 1 |
| Lee, J | 1 |
| Said, Q | 1 |
| Neary, MP | 1 |
| Biller, BMK | 1 |
| Parsanezhad, ME | 1 |
| Alborzi, S | 1 |
| Pakniat, M | 1 |
| Schmidt, EH | 1 |
| Owj, M | 1 |
| Tehrani-Nejad, ES | 1 |
| Amirchaghmaghi, E | 1 |
| Baghestani, AR | 1 |
| Ahmadi, J | 1 |
| Vidal-Puig, A | 1 |
| Muñoz-Torres, M | 1 |
| Garcia-Calvente, C | 1 |
| Jodar-Gimeno, E | 1 |
| Lardelli, P | 1 |
| Ruiz-Requena, ME | 1 |
| Escobar-Jiménez, F | 1 |
| Gal, M | 2 |
| Orly, J | 2 |
| Barr, I | 2 |
| Algur, N | 1 |
| Boldes, R | 1 |
| Diamant, YZ | 2 |
| Gökmen, O | 1 |
| Senöz, S | 1 |
| Gülekli, B | 1 |
| Işik, AZ | 1 |
| Eldar-Geva, T | 1 |
| Margalioth, EJ | 1 |
| Ali Hassan, H | 1 |
| El-Gezeiry, D | 1 |
| Nafaa, TM | 1 |
| Baghdady, I | 1 |
| Cedeno, J | 1 |
| Mendoza, SG | 1 |
| Velazquez, E | 1 |
| Nucete, H | 1 |
| Speirs, J | 1 |
| Glueck, CJ | 1 |
6 trials available for ketoconazole and Polycystic Ovary Syndrome
| Article | Year |
|---|---|
A double-blind, randomized, placebo-controlled study to assess the efficacy of ketoconazole for reducing the risk of ovarian hyperstimulation syndrome.
Topics: Adult; Androgen Antagonists; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combin | 2003 |
The role of ketoconazole in the prevention of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during assisted reproductive technology cycles.
Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fertilization in Vitr | 2005 |
Comparison of four different treatment regimes in hirsutism related to polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgen Antagonists; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Contrac | 1996 |
Attenuation of ovarian response by low-dose ketoconazole during superovulation in patients with polycystic ovary syndrome.
Topics: Adolescent; Adult; Cross-Over Studies; Dose-Response Relationship, Drug; Estradiol; Female; Humans; | 1999 |
Improved responsiveness of PCOS patients to clomiphene after CYP17a inhibitor.
Topics: Clomiphene; Estrogen Antagonists; Female; Humans; Insulin; Ketoconazole; Polycystic Ovary Syndrome; | 2001 |
Effect of ketoconazole on plasma sex hormones, lipids, lipoproteins, and apolipoproteins in hyperandrogenic women.
Topics: Adolescent; Adult; Androgens; Apolipoproteins; Cholesterol; Dehydroepiandrosterone; Dehydroepiandros | 1990 |
3 other studies available for ketoconazole and Polycystic Ovary Syndrome
| Article | Year |
|---|---|
BIOCHEMICAL CONTROL DURING LONG-TERM FOLLOW-UP OF 230 ADULT PATIENTS WITH CUSHING DISEASE: A MULTICENTER RETROSPECTIVE STUDY.
Topics: 14-alpha Demethylase Inhibitors; ACTH-Secreting Pituitary Adenoma; Adenoma; Adolescent; Adrenalectom | 2017 |
Reduction of endogenous, ovarian and adrenal androgens with ketoconazole does not alter insulin response in the polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Drug Administration Schedule; Female; Humans; Insulin; Ketoconazole; P | 1994 |
Low dose ketoconazole attenuates serum androgen levels in patients with polycystic ovary syndrome and inhibits ovarian steroidogenesis in vitro.
Topics: 17-alpha-Hydroxyprogesterone; 17-Hydroxysteroid Dehydrogenases; Administration, Oral; Adrenocorticot | 1994 |